Haofeng Ji1, Yuanxing Liu1,2, Yu Zhang1,2, Xiu-da Shen1, Feng Gao1, Ronald W Busuttil1, Vijay K Kuchroo3, Jerzy W Kupiec-Weglinski1. 1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA. 2. Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 3. Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
UNLABELLED: Hepatic ischemia-reperfusion injury (IRI), an innate immunity-driven inflammation response, occurs in multiple clinical settings including liver resection, transplantation, trauma, and shock. T-cell immunoglobulin and mucin (TIM)-4, the only TIM protein not expressed on T cells, is found on macrophages and dendritic cells. The regulatory function of macrophage TIM-4 in the engulfment of apoptotic/necrotic bodies in innate immunity-mediated disease states remains unknown. This study focuses on the putative role of TIM-4 signaling in a model of liver warm ischemia (90 minutes) and reperfusion. The ischemia insult triggered TIM-4 expression by stressed hepatocellular phosphatidylserine (PS) presentation, peaking at 6 hours of reperfusion, and coinciding with the maximal hepatocellular damage. TIM-4-deficient or wild-type WT mice treated with antagonistic TIM-4 monoclonal antibody (mAb) were resistant against liver IRI, evidenced by diminished serum alanine aminotransferase (sALT) levels and well-preserved hepatic architecture. Liver hepatoprotection rendered by TIM-4 deficiency was accompanied by diminished macrophage infiltration/chemoattraction, phagocytosis, and activation of Toll-like receptor (TLR)2/4/9-dependent signaling. Correlating with in vivo kinetics, the peak of TIM-4 induction in lipopolysaccharide (LPS)-activated bone marrow derived-macrophages (BMM) was detected in 6-hour cultures. To mimic liver IRI, we employed hydrogen peroxide-necrotic hepatocytes, which readily present PS. Indeed, necrotic hepatocytes were efficiently captured/engulfed by WT (TIM-4+) but not by TIM-4-deficient BMM. Finally, in a newly established model of liver IRI, adoptive transfer of WT but not TIM-4-deficient BMM readily recreated local inflammation response/hepatocellular damage in the CD11b-DTR mouse system. CONCLUSION: These findings document the importance of macrophage-specific TIM-4 activation in the mechanism of hepatic IRI. Macrophage TIM-4 may represent a therapeutic target to minimize innate inflammatory responses in IR-stressed organs.
UNLABELLED: Hepatic ischemia-reperfusion injury (IRI), an innate immunity-driven inflammation response, occurs in multiple clinical settings including liver resection, transplantation, trauma, and shock. T-cell immunoglobulin and mucin (TIM)-4, the only TIM protein not expressed on T cells, is found on macrophages and dendritic cells. The regulatory function of macrophage TIM-4 in the engulfment of apoptotic/necrotic bodies in innate immunity-mediated disease states remains unknown. This study focuses on the putative role of TIM-4 signaling in a model of liver warm ischemia (90 minutes) and reperfusion. The ischemia insult triggered TIM-4 expression by stressed hepatocellular phosphatidylserine (PS) presentation, peaking at 6 hours of reperfusion, and coinciding with the maximal hepatocellular damage. TIM-4-deficient or wild-type WT mice treated with antagonistic TIM-4 monoclonal antibody (mAb) were resistant against liver IRI, evidenced by diminished serum alanine aminotransferase (sALT) levels and well-preserved hepatic architecture. Liver hepatoprotection rendered by TIM-4 deficiency was accompanied by diminished macrophage infiltration/chemoattraction, phagocytosis, and activation of Toll-like receptor (TLR)2/4/9-dependent signaling. Correlating with in vivo kinetics, the peak of TIM-4 induction in lipopolysaccharide (LPS)-activated bone marrow derived-macrophages (BMM) was detected in 6-hour cultures. To mimic liver IRI, we employed hydrogen peroxide-necrotic hepatocytes, which readily present PS. Indeed, necrotic hepatocytes were efficiently captured/engulfed by WT (TIM-4+) but not by TIM-4-deficient BMM. Finally, in a newly established model of liver IRI, adoptive transfer of WT but not TIM-4-deficient BMM readily recreated local inflammation response/hepatocellular damage in the CD11b-DTR mouse system. CONCLUSION: These findings document the importance of macrophage-specific TIM-4 activation in the mechanism of hepatic IRI. Macrophage TIM-4 may represent a therapeutic target to minimize innate inflammatory responses in IR-stressed organs.
Authors: Haofeng Ji; Yu Zhang; Xiu-da Shen; Feng Gao; Cynthia Y Huang; Catalina Abad; Ronald W Busuttil; James A Waschek; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2013-01-18 Impact factor: 17.425
Authors: Roselynn Rodriguez-Manzanet; Miguel A Sanjuan; Henry Y Wu; Francisco J Quintana; Sheng Xiao; Ana C Anderson; Howard L Weiner; Douglas R Green; Vijay K Kuchroo Journal: Proc Natl Acad Sci U S A Date: 2010-04-05 Impact factor: 11.205
Authors: Haofeng Ji; Xiuda Shen; Feng Gao; Bibo Ke; Maria Cecilia S Freitas; Yoichiro Uchida; Ronald W Busuttil; Yuan Zhai; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2010-10 Impact factor: 17.425
Authors: Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Nat Rev Gastroenterol Hepatol Date: 2012-12-11 Impact factor: 46.802
Authors: Zubin M Bamboat; Vinod P Balachandran; Lee M Ocuin; Hebroon Obaid; George Plitas; Ronald P DeMatteo Journal: Hepatology Date: 2010-02 Impact factor: 17.425
Authors: Y Zhang; H Ji; X Shen; J Cai; F Gao; K M Koenig; C M Batikian; R W Busuttil; J W Kupiec-Weglinski Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086
Authors: Sean E Doyle; Ryan M O'Connell; Gustavo A Miranda; Sagar A Vaidya; Edward K Chow; Philip T Liu; Shinobu Suzuki; Nobutaka Suzuki; Robert L Modlin; Wen-Chen Yeh; Timothy F Lane; Genhong Cheng Journal: J Exp Med Date: 2003-12-29 Impact factor: 14.307
Authors: Jin Xu; Zhengze Xue; Cheng Zhang; Yuan Liu; Ronald W Busuttil; Jiamin Zhang; Jerzy W Kupiec-Weglinski; Haofeng Ji Journal: Transplantation Date: 2019-04 Impact factor: 4.939
Authors: Kojiro Nakamura; Shoichi Kageyama; Bibo Ke; Takehiro Fujii; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Liver Transpl Date: 2017-10 Impact factor: 5.799
Authors: Tiziana Palumbo; Kojiro Nakamura; Charles Lassman; Yoko Kidani; Steven J Bensinger; Ronald Busuttil; Jerzy Kupiec-Weglinski; Ali Zarrinpar Journal: Transplantation Date: 2017-02 Impact factor: 4.939
Authors: C Zhang; Y Zhang; Y Liu; Y Liu; S Kageyama; X-D Shen; F Gao; S Zheng; R W Busuttil; G D Shaw; H Ji; J W Kupiec-Weglinski Journal: Am J Transplant Date: 2017-02-06 Impact factor: 8.086
Authors: Kojiro Nakamura; Min Zhang; Shoichi Kageyama; Bibo Ke; Takehiro Fujii; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jesus A Araujo; Jerzy W Kupiec-Weglinski Journal: J Hepatol Date: 2017-08-23 Impact factor: 25.083
Authors: Yuan Liu; Tianfei Lu; Cheng Zhang; Jin Xu; Zhengze Xue; Ronald W Busuttil; Ning Xu; Qiang Xia; Jerzy W Kupiec-Weglinski; Haofeng Ji Journal: J Hepatol Date: 2019-06-13 Impact factor: 25.083
Authors: Shi Yue; Haoming Zhou; Xuehao Wang; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Yuan Zhai Journal: J Immunol Date: 2017-03-13 Impact factor: 5.422